LQ-38

• UNSPSC Description:

  LQ-38 is an orally active inhibitor for soluble epoxide hydrolase (sEH) with an IC50 of 5.2 nM. LQ-38 exhibits anti-inflammatory activity in rat foot edema model and mouse acute pancreatitis model, exhibits analgesic effect in Acetic acid (HY-Y0319)-induced writhing mouse model[1].

• Target Antigen:

  Epoxide Hydrolase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/lq-38.html

• Smiles:

  C[C@]1(CNC(NCC2CCOCC2)=O)CC[C@]([C@]3([H])C1)(C)CCC(C3=C4)[C@]5(C)CC[C@@]6([H])C(C)(C)[C@@H](O[C@@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)CC[C@]6(C)[C@@]5([H])C4=O

• Molecular Weight:

  745.00

• References & Citations:

  [1]Liu Q, et al., Discovery of glycosidated glycyrrhetinic acid derivatives: Natural product-based soluble epoxide hydrolase inhibitors. Eur J Med Chem. 2024 Oct 9;280:116937.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported